Acquisitiuon

Creso Pharma set to be the first ASX listed entrant in new market

Finfeed Archived Mar 15, 2021

Creso Pharma Limited (ASX:CPH, FRA:1X8) has signed an agreement to acquire Halucenex Life Sciences Inc. (Halucenex), an established psychedelics company focused on developing treatments for Treatment Resistant Depression in individuals suffering from PTSD, and other mental health illnesses.